Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Anaphylactic Shock | Coronavirus | Covid Vaccine | COVID-19 | Japan Health | Marketing | Research | Respiratory Medicine | SARS | Study | Vaccines